Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Pilot Study of Bisphosphonates for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02781805
Recruitment Status : Recruiting
First Posted : May 24, 2016
Last Update Posted : January 18, 2020
Sponsor:
Collaborator:
Wisconsin Partnership Program
Information provided by (Responsible Party):
University of Wisconsin, Madison

Brief Summary:
The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell differentiation of high-risk women. To this end, we have designed a BP "window trial" to examine the effect of 1 - 3 weeks administration of alendronate on women at high-risk for breast cancer, at the level of immunosurveillance and mammary epithelial cell differentiation.

Condition or disease Intervention/treatment Phase
Breast Neoplasms Drug: Alendronate Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Pilot Clinical Trial of Short-Term Bisphosphonate Administration as Chemoprevention for Breast Cancer Via Engagement of γδ T Cells
Actual Study Start Date : August 5, 2016
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : March 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Alendronate
Subjects will take the study drug alendronate, a nitrogenous bisphosponate, for approximately one to three weeks before their breast surgery.
Drug: Alendronate
10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
Other Names:
  • Fosamax
  • Binosto




Primary Outcome Measures :
  1. Percentage change of γδ T cell in CNB [ Time Frame: 1-3 weeks ]
    γδ T cell infiltration and activation as defined by the presence and increase in percentage of γδ T cells in the CNB sample following study agent (alendronate) administration. The effect of alendronate will be assessed using a one-tailed one-sample paired t-test or Wilcoxon signed rank test at a significance level of 0.10.


Secondary Outcome Measures :
  1. Percentage change of mammary epithelial basal cells in the CNB samples after alendronate administration [ Time Frame: 1-3 weeks ]
    The effect of alendronate will be assessed using a one-tailed one-sample paired t-test or Wilcoxon signed rank test at a significance level of 0.10.

  2. Percentage change of mammary luminal cells in the CNB samples after alendronate administration [ Time Frame: 1-3 weeks ]
    The effect of alendronate will be assessed using a one-tailed one-sample paired t-test or Wilcoxon signed rank test at a significance level of 0.10.


Other Outcome Measures:
  1. Percentage change of γδ T cells in the blood [ Time Frame: 1-3 weeks ]
    The effect of alendronate will be assessed using a one-tailed one-sample paired t-test or Wilcoxon signed rank test at a significance level of 0.10.

  2. Ratio of percent of luminal cells to percent of basal cells in CNB [ Time Frame: 1-3 weeks ]
    The effect of alendronate will be assessed using a one-tailed one-sample paired t-test or Wilcoxon signed rank test at a significance level of 0.10.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients referred for risk reduction mastectomy (eg. BRCA or other high-risk gene mutations, strong family history of breast cancer, prior or current LCIS, ADH, ALH and DCIS undergoing bilateral mastectomy or prophylactic contralateral mastectomy), oe patients at high-risk for breast cancer (eg. BRCA or other high-risk gene mutations, strong family history of breast cancer, prior or current LCIS, ADH, ALH and DCIS) who are not planning for immediate risk reduction mastectomy and are undergoing routine follow-up.
  • Patients who are premenopausal defined as an individual with at least six menstrual cycles in the past year, women with hysterectomy with intact functioning ovaries who are not having menstrual cycles need to be 45 years of age and under.
  • Patients must be 18 years of age or older
  • The effects of Alendronate on the developing fetus are unknown. For this reason, sexually active heterosexual women must agree to use an effective form of birth control for the duration of study participation. Women who are NOT having 1) a hysterectomy, 2) fallopian tubes removed and/or 3) ovaries removed at the time of their breast surgery will also be required to use an effective form of birth control for 56 days following the last dose of study medication. In addition to, premenopausal women who are undergoing routine follow up and are not having surgery will be required to use an effective form of birth control for 56 days following the last dose of study medication. One of the following methods of birth control must be used by sexually active women of childbearing potential:

    • Oral contraceptive pill in continuous use for >90 days prior to study entry
    • Vaginal ring in continuous use for >90 days prior to study entry
    • Skin patch in continuous use for >90 days prior to study entry
    • Injection in continuous use prior to study entry
    • IUD
    • Diaphragm, cervical cap, or cervical shield with spermicide
    • Contraceptive sponge
    • Condom (male or female type) plus spermicide
    • Male partner who has had a vasectomy
  • Women who are abstinent from heterosexual encounters for the duration of the study participation and for the 56 days following the last dose of study medication will not be required to uses birth control.
  • Women with hysterectomy with intact functioning ovaries, women with Fallopian tubes cut, tied, or sealed, and women with a sterilization implant (e.g. Adiana, Essure) placed >3 months prior to beginning the study drug are not considered to be able to bear children and therefore are eligible to participate without the use of concurrent birth control.
  • Females of child-bearing potential must have a negative pregnancy test within the current menstrual cycle and within 7 days before starting drug.
  • Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
  • Participants must have the ability to understand, and the willingness to sign, a written informed consent form

Exclusion Criteria:

  • Patients with a previous diagnosis of invasive breast cancer
  • Patients who are post-menopausal (defined as 12 consecutive months without a menstrual period).
  • Patients with an implant in the sampled breast
  • Pregnant or lactating women are excluded from this study. Breastfeeding must be discontinued for the duration of study participation and for 8 weeks after the last dose of the study agent
  • Patients for whom English is not their native language
  • Patients with current or previous bisphosphonate therapy
  • Patients with a history of allergic reactions attributed to compounds of similar chemical or biologic composition of alendronate and other bisphosphonates.
  • Patients with esophageal dysmotility
  • Patients unable to sit up or stay up for 30 minutes after taking oral dose
  • Patients who have taken non-steroidal anti-inflammatory drugs (NSAIDs) in the past two weeks
  • Patients who have received chemotherapy for a malignancy in the past 5 years
  • Patients who are treated for a medical condition (such as ulcerative colitis) with chronic steroids within the last 2 years
  • Patients with calculated creatinine clearance (Cockroft-Gault) less than 35 mL/min
  • Patients with a history of hypocalcemia
  • Bilateral DCIS, LCIS, ADH or ALH

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02781805


Contacts
Layout table for location contacts
Contact: Cancer Connect 800-622-8922 clinicaltrials@cancer.wisc.edu

Locations
Layout table for location information
United States, Wisconsin
University of Wisconsin Carbone Cancer Center Recruiting
Madison, Wisconsin, United States, 53705
Contact: Cancer Connect    800-622-8922    clinicaltrials@cancer.wisc.edu   
Principal Investigator: Lee Wilke         
Sponsors and Collaborators
University of Wisconsin, Madison
Wisconsin Partnership Program
Investigators
Layout table for investigator information
Principal Investigator: Lee Wilke University of Wisconsin, Madison

Additional Information:
Layout table for additonal information
Responsible Party: University of Wisconsin, Madison
ClinicalTrials.gov Identifier: NCT02781805    
Other Study ID Numbers: UW13060
2016-0322 ( Other Identifier: Institutional Review Board )
A539997 ( Other Identifier: UW Madison )
SMPH\VOLUNTEER STAFF\SURGERY ( Other Identifier: UW Madison )
NCI-2016-00786 ( Registry Identifier: NCI Trial ID )
First Posted: May 24, 2016    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: December 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Alendronate
Diphosphonates
Bone Density Conservation Agents
Physiological Effects of Drugs